Esperion Therapeutics Inc.
3621 S. State Street
695 KMS Place
About Esperion Therapeutics Inc.Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.
The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.
Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.
President and CEO
Chief Operating Officer and CFO
Last Updated: 01-18-05
184 articles with Esperion Therapeutics Inc.
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
Esperion provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
Esperion announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
Esperion announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd.
9/9/2019Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
Esperion announced the completion of patient enrollment in the CLEAR Cardiovascular Outcomes Trial.
9/3/2019Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
Esperion announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units to eighteen new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study.
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
Esperion provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.
Esperion announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology Conference in New York, NY on Monday, August 12, 2019 at 11:00 a.m. Eastern Time.
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
Esperion and an investor group led by Oberland Capital Management LLC announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.
Esperion announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of stockholders.
Esperion announced that the company will participate in analyst-led fireside chats with investors at the following conferences
Esperion today announced that the company will participate in analyst-led fireside chats with investors at the following conferences
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
Esperion provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019.
Esperion announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time.
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver
Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors
Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached their fiduciary duties to shareholders.